Specifically, at the systemic level, flow cytometry and ELISA detection confirm that the combined treatment significantly reduces the proportion of Treg cells in peripheral blood and the levels of serum immunosuppressive factors IL-10 and TGF-β1; at the tissue molecular level, Western blot analysis further shows that the protein expression of TGF-β1 and its downstream key functional molecule Foxp3 in tumor local tissues is also simultaneously downregulated. The gene discussed is TGFB1; the disease is neoplasm.